oncoscan Search Results


oncoscan  (INFINIUM Inc)
90
INFINIUM Inc oncoscan
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Oncoscan, supplied by INFINIUM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/oncoscan/pmc09749332-50-26-32
Average 90 stars, based on 1 article reviews
oncoscan - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
oncoscan console software  (BioDiscovery Inc)
90
BioDiscovery Inc oncoscan console software
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Oncoscan Console Software, supplied by BioDiscovery Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/oncoscan+console+software/pmc05354893-181-11-14
Average 90 stars, based on 1 article reviews
oncoscan console software - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
snp-fasst2 segmentation statistical algorithm in nexus software v7.5  (BioDiscovery Inc)
90
BioDiscovery Inc snp-fasst2 segmentation statistical algorithm in nexus software v7.5
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Snp Fasst2 Segmentation Statistical Algorithm In Nexus Software V7.5, supplied by BioDiscovery Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/nexus+express+oncoscan+software+version+7+5/pmc05696154-117-20-23
Average 90 stars, based on 1 article reviews
snp-fasst2 segmentation statistical algorithm in nexus software v7.5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
oncoscan cnv assay  (WholeGenome LLC)
90
WholeGenome LLC oncoscan cnv assay
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Oncoscan Cnv Assay, supplied by WholeGenome LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/oncoscan+cnv+assay/10__21608_slash_jmalexu__2025__349090__1045-133-2-7
Average 90 stars, based on 1 article reviews
oncoscan cnv assay - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
oncoscan array  (BioDiscovery Inc)
90
BioDiscovery Inc oncoscan array
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Oncoscan Array, supplied by BioDiscovery Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/oncoscan+array/pmc07456611__oncotarget___11___3227___s001-6-24-44
Average 90 stars, based on 1 article reviews
oncoscan array - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
chromosomal microarray analysis oncoscan  (Pyrosequencing Inc)
86
Pyrosequencing Inc chromosomal microarray analysis oncoscan
Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) <t>OncoScan</t> and <t>(B)</t> <t>Infinium</t> CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number
Chromosomal Microarray Analysis Oncoscan, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncoscan/analysis+chromosomal+microarray+oncoscan/pmc12953305-89-22-18
Average 86 stars, based on 1 article reviews
chromosomal microarray analysis oncoscan - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
oncoscan cnv plus reagent kit  (Thermo Fisher)
N/A
The OncoScan CNV Plus Reagent Kit is part of the OncoScan CNV Plus Assay and so is used in conjunction with OncoScan CNV Plus arrays. The OncoScan CNV Plus Reagent Kit contains somatic mutation probe
   Buy from Supplier
oncoscan ffpe services  (Thermo Fisher)
N/A
Applied Biosystems OncoScan Assay Services accelerate your projects. Discover new biomarkers for diagnosis, prognostics, or predictive research by looking at whole genome copy number changes. OncoScan Assay service providers work collaboratively with you to achieve
   Buy from Supplier
oncoscan cnv assay  (Thermo Fisher)
N/A
The OncoScan CNV Assay is a whole-genome copy number microarray-based assay that enables the detection of relevant copy number variations (CNVs) such as copy number gain and loss, loss of heterozygosity (LOH), copy neutral loss
   Buy from Supplier
oncoscan cnv reagent kit  (Thermo Fisher)
N/A
The OncoScan CNV Reagent Kit is part of the OncoScan CNV Assay and so is used in conjunction with OncoScan CNV arrays. The OncoScan CNV Reagent Kit contains the copy number probe mix and controls,
   Buy from Supplier
oncoscan cnv ffpe services  (Thermo Fisher)
N/A
Discover new biomarkers for diagnosis, prognostics, or predictive research by looking at whole genome copy number changes Tumors usually arise from normal cells with tissue-specific acquired mutations or aberrations in their genomic materials. Copy number
   Buy from Supplier
oncoscan cnv plus assay  (Thermo Fisher)
N/A
The OncoScan CNV Plus Assay is a whole-genome copy number microarray-based assay that enables the detection of relevant copy number variations (CNVs) such as copy number gain and loss, loss of heterozygosity (LOH), copy neutral
   Buy from Supplier

Image Search Results


Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) OncoScan and (B) Infinium CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number

Journal: BMC Cancer

Article Title: Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test

doi: 10.1186/s12885-022-10197-z

Figure Lengend Snippet: Patient-level genomic metrics by BRCA m or HRD status with the clinically validated HRD test. (A) OncoScan and (B) Infinium CytoSNP-850K by BRCA m status, and (C) OncoScan and (D) Infinium CytoSNP-850K by HRD status. Orange indicates non– BRCA m tumors or HRD negative tumors by the clinically validated HRD test; green indicates deleterious BRCA m tumors or tumors deemed HRD positive by the clinically validated HRD test. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number

Article Snippet: ASCAT was then used to evaluate copy number variation (CNV) and LOH (Fig. ) using log R ratio and B-allele frequency of 205,647 autosomal markers for OncoScan and 789,872 autosomal markers for Infinium CytoSNP-850K, with GC wave correction [ ].

Techniques: Mutagenesis, Homologous Recombination

Correlation with GC correction between genomic metrics and the clinically validated HRD test. (A) OncoScan. (B) Infinium CytoSNP-850K. Orange circles indicate non– BRCA m tumors; green circles indicate deleterious BRCA m tumors. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number

Journal: BMC Cancer

Article Title: Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test

doi: 10.1186/s12885-022-10197-z

Figure Lengend Snippet: Correlation with GC correction between genomic metrics and the clinically validated HRD test. (A) OncoScan. (B) Infinium CytoSNP-850K. Orange circles indicate non– BRCA m tumors; green circles indicate deleterious BRCA m tumors. BRCA m, mutation in BRCA1, BRCA2 , or both; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number

Article Snippet: ASCAT was then used to evaluate copy number variation (CNV) and LOH (Fig. ) using log R ratio and B-allele frequency of 205,647 autosomal markers for OncoScan and 789,872 autosomal markers for Infinium CytoSNP-850K, with GC wave correction [ ].

Techniques: Mutagenesis, Homologous Recombination

Correlation between HRD sum score by SNP genotyping assays and the clinically validated HRD test following SNP downsampling. (A) OncoScan. (B) Infinium CytoSNP-850K. HRD, homologous recombination deficiency; SNP, single-nucleotide polymorphism

Journal: BMC Cancer

Article Title: Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test

doi: 10.1186/s12885-022-10197-z

Figure Lengend Snippet: Correlation between HRD sum score by SNP genotyping assays and the clinically validated HRD test following SNP downsampling. (A) OncoScan. (B) Infinium CytoSNP-850K. HRD, homologous recombination deficiency; SNP, single-nucleotide polymorphism

Article Snippet: ASCAT was then used to evaluate copy number variation (CNV) and LOH (Fig. ) using log R ratio and B-allele frequency of 205,647 autosomal markers for OncoScan and 789,872 autosomal markers for Infinium CytoSNP-850K, with GC wave correction [ ].

Techniques: Homologous Recombination